Home > Publications database > The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis. > print

001     305425
005     20251020115508.0
024 7 _ |a 10.3390/ijms26199811
|2 doi
024 7 _ |a pmid:41097076
|2 pmid
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
037 _ _ |a DKFZ-2025-02154
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Jennemann, Richard
|0 P:(DE-He78)3caae9893e3b2704f7bb5a9646ef084d
|b 0
|e First author
|u dkfz
245 _ _ |a The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis.
260 _ _ |a Basel
|c 2025
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1760947140_1189494
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A411#LA:A411#
520 _ _ |a Modern computational screening methods are valuable tools for repurposing approved drugs for novel therapeutic applications. They provide initial insights into alternative uses and may significantly shorten the lengthy process of drug development and regulatory approval. Treatment options for glycosphingolipidoses, lysosomal storage diseases involving glycosphingolipids (GSLs), are currently limited to a few drugs that inhibit de novo GSL biosynthesis, such as eliglustat and miglustat (Zavesca®). In the search for alternative drugs, dapagliflozin emerged as a promising candidate for off-target therapy. In the present study, we investigated whether dapagliflozin can indeed inhibit GSL synthesis, as predicted by previous computational analyses, and compared its effects with those of the glycosphingolipid synthesis inhibitor, the eliglustat analog Genz-123346, in murine 3T3 and Hepa 1-6 cell lines. While Genz-123346 significantly inhibited glycosphingolipid biosynthesis at concentrations as low as 1 µM, dapagliflozin, even up to 50 µM, had no effect on biosynthesis or de novo biosynthesis in either cell line. These results indicate that dapagliflozin, although assessing effects on the cell cycle, including proliferation at high concentrations, is not a suitable candidate for treating glycosphingolipid storage diseases by substrate reduction.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a GCS-inhibitors
|2 Other
650 _ 7 |a Genz-123346
|2 Other
650 _ 7 |a dapagliflozin
|2 Other
650 _ 7 |a eliglustat
|2 Other
650 _ 7 |a glucosylceramide synthase (GCS)
|2 Other
650 _ 7 |a glycosphingolipids
|2 Other
650 _ 7 |a miglustat
|2 Other
650 _ 7 |a Glucosides
|2 NLM Chemicals
650 _ 7 |a Benzhydryl Compounds
|2 NLM Chemicals
650 _ 7 |a Glycosphingolipids
|2 NLM Chemicals
650 _ 7 |a dapagliflozin
|0 1ULL0QJ8UC
|2 NLM Chemicals
650 _ 7 |a Sodium-Glucose Transporter 2 Inhibitors
|2 NLM Chemicals
650 _ 7 |a Sodium-Glucose Transporter 2
|2 NLM Chemicals
650 _ 2 |a Glucosides: pharmacology
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Benzhydryl Compounds: pharmacology
|2 MeSH
650 _ 2 |a Glycosphingolipids: biosynthesis
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Sodium-Glucose Transporter 2 Inhibitors: pharmacology
|2 MeSH
650 _ 2 |a Cell Cycle: drug effects
|2 MeSH
650 _ 2 |a Cell Line
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Sodium-Glucose Transporter 2: metabolism
|2 MeSH
700 1 _ |a Sandhoff, Roger
|0 P:(DE-He78)a928ded2085c8911822370cad0b4a728
|b 1
|e Last author
|u dkfz
773 _ _ |a 10.3390/ijms26199811
|g Vol. 26, no. 19, p. 9811 -
|0 PERI:(DE-600)2019364-6
|n 19
|p 9811
|t International journal of molecular sciences
|v 26
|y 2025
|x 1422-0067
909 C O |o oai:inrepo02.dkfz.de:305425
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)3caae9893e3b2704f7bb5a9646ef084d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)a928ded2085c8911822370cad0b4a728
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-21
920 2 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 0
920 1 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 0
920 0 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A411-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21